Benserazide has been used:• to inhibit dopa-decarboxylase• to induce dyskinesia• to test on purified bacterial TDCs to assess the extent to which it could affect bacterial decarboxylases• as a peripheral dopa decarboxylase inhibitor to treat mice
Benserazide can block HK2 enzymatic activity in vitro. It is used along with levodopa to treat Parkinson's disease.
Inhibitor of L-aromatic amino acid decarboxylase.
Features and Benefits
This compound was developed by Roche. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
This compound is also offered as part of Sigma′s Library of Pharmacologically Active Compounds (LOPAC®1280), a biologically annotated collection of high-quality, ready-to-screen compounds. Click here to learn more.
This compound is a featured product for Neuroscience research. Click here to discover more featured Neuroscience products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
Benserazide is a peripheral decarboxylase inhibitor.
LOPAC is a registered trademark of Sigma-Aldrich Co. LLC